Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.07.012
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2018
Authors
Publisher
Elsevier BV